PT - JOURNAL ARTICLE AU - Green, David J. AU - Lenassi, Eva AU - Manning, Cerys S. AU - McGaughey, David AU - Sharma, Vinod AU - Black, Graeme C. AU - Ellingford, Jamie M. AU - Sergouniotis, Panagiotis I. TI - North Carolina macular dystrophy: phenotypic variability and computational analysis of disease-implicated non-coding variants AID - 10.1101/2021.03.05.21252975 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.05.21252975 4099 - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252975.short 4100 - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252975.full AB - Purpose North Carolina macular dystrophy (NCMD) is an autosomal dominant, congenital disorder affecting the central retina. Here, we report clinical and genetic findings in three families segregating NCMD and use epigenomic datasets from human tissues to gain insights into the effect of NCMD-implicated variants.Methods Clinical assessment and genetic testing were performed. Publicly-available transcriptomic and epigenomic datasets were analyzed and the ‘Activity-by-Contact’ (ABC) method for scoring enhancer elements and linking them to target genes was used.Results A previously-described, heterozygous, non-coding variant upstream of the PRDM13 gene was detected in all six affected study participants (chr6:100,040,987G>C [GRCh37/hg19]). Inter- and intra-familial variability were observed; the visual acuity ranged from 0.0 to 1.6 LogMAR and fundoscopic findings ranged from visually insignificant, confluent, drusen-like macular deposits to coloboma-like macular lesions. Variable degrees of peripheral retinal spots (which were easily detected on widefield retinal imaging) were observed in all study subjects. Notably, a 6-year-old patient developed choroidal neovascularization and required treatment with intravitreal bevacizumab injections. Computational analysis of the five single nucleotide variants that have been implicated in NCMD revealed that these non-coding changes lie within two putative enhancer elements; these elements are predicted to interact with PRDM13 in the developing human retina. PRDM13 was found to be expressed in the fetal retina, with highest expression in the amacrine precursor cell population.Conclusions We provide further evidence supporting the role of PRDM13 dysregulation in the pathogenesis of NCMD and highlight the utility of widefield retinal imaging in individuals suspected to have this condition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementChristopher Green Doctoral Fellowship (DJG), UK National Institute for Health Research (NIHR) Clinical Lecturer Award (CL-2017-06-001, PIS), Health Education England Postdoctoral Research Fellowship (JME), Wellcome Trust Sir Henry Wellcome Fellowship (103986/Z/14/Z, CSM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee approval for the study was obtained from the North West Research Ethics Committee (11/NW/0421 and 15/YH/0365) and all investigations were conducted in accordance to the tenets of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicly available. Epigenomic and transcriptomic data are available through GEO (accession: GSE137311). The ABC enhancer prediction tool is available on GitHub (https://github.com/broadinstitute/ABC-Enhancer-Gene-Prediction).